

# K-Paths: Reasoning over Graph Paths for Drug Repurposing and Drug Interaction Prediction

Tassallah Abdullahi  
tassallah\_abdullahi@brown.edu  
Brown University  
Providence, RI, USA

Ioanna Gemou  
ioanna\_gemou@brown.edu  
Brown University  
Providence, RI, USA

Nihal V. Nayak  
nihal\_vivekanand\_nayak@brown.edu  
Brown University  
Providence, RI, USA

Ghulam Murtaza  
ghulam\_murtaza@brown.edu  
Brown University  
Providence, RI, USA

Stephen H. Bach  
stephen\_bach@brown.edu  
Brown University  
Providence, RI, USA

Carsten Eickhoff\*  
carsten.eickhoff@uni-tuebingen.de  
University of Tübingen  
Tübingen, Germany

Ritambhara Singh\*  
ritambhara@brown.edu  
Brown University  
Providence, RI, USA

## Abstract

Drug discovery is a complex and time-intensive process that requires identifying and validating new therapeutic candidates. Computational approaches using large-scale biomedical knowledge graphs (KGs) offer a promising solution to accelerate this process. However, extracting meaningful insights from large-scale KGs remains challenging due to the complexity of graph traversal. Existing subgraph-based methods are tailored to graph neural networks (GNNs), making them incompatible with other models, such as large language models (LLMs). We introduce K-Paths, a retrieval framework that extracts structured, diverse, and biologically meaningful paths from KGs. Integrating these paths enables LLMs and GNNs to effectively predict unobserved drug-drug and drug-disease interactions. Unlike traditional path-ranking approaches, K-Paths retrieves and transforms paths into a structured format that LLMs can directly process, facilitating explainable reasoning. K-Paths employs a diversity-aware adaptation of Yen’s algorithm to retrieve the K shortest loopless paths between entities in an interaction query, prioritizing biologically relevant and diverse relationships. Our experiments on benchmark datasets show that K-Paths improves the zero-shot performance of Llama 8.1B’s F1-score by 12.45 points on drug repurposing and 13.42 points on interaction severity prediction. We also show that Llama 70B achieves F1-score gains of 6.18 and 8.46 points, respectively. K-Paths also improves the supervised training efficiency of EmerGNN, a state-of-the-art GNN, by reducing KG size by 90% while maintaining strong predictive performance. Beyond its scalability and efficiency, K-Paths uniquely bridges the gap between KGs and LLMs, providing explainable rationales for predicted interactions. These capabilities show that K-Paths is a valuable tool for efficient data-driven drug discovery<sup>1</sup>.

## CCS Concepts

• **Computing methodologies** → **Knowledge representation and reasoning.**

\*co-corresponding authors.

<sup>1</sup>code available at: <https://github.com/rsinghlab/K-Paths>

## Keywords


Knowledge graph reasoning, Drug Discovery, Large Language Models, Graph Neural Networks, Model Explainability

## 1 Introduction

Drug development and safety assessment have traditionally been time-intensive and costly, often spanning years and requiring billions of dollars [12, 34]. However, recent increases in computational power and the amount of available clinical and biological data are transforming this landscape, enabling faster and more cost-effective approaches to discovering and validating safer drugs [8, 22, 38]. For instance, deep learning models trained on genomic and chemical datasets now predict drug efficacy and toxicity with high accuracy, reducing the reliance on extensive laboratory experiments and accelerating the drug discovery process [9]. Yet, the sheer volume and heterogeneity of these datasets pose integration challenges, making it difficult to extract meaningful insights [10, 18].

Knowledge Graphs (KGs) offer a structured solution by integrating complex biological relationships, linking diseases, drugs, and proteins into an interconnected framework [8, 21, 27], offering a rich resource for understanding and predicting mechanisms and interactions. Despite their potential, the scale and complexity of KGs can hinder the efficient retrieval of relevant information [35]. While typical KGs contain tens of thousands of nodes and millions of edges, only a small subgraph is relevant for a given task [46], limiting their practical applications in critical areas like drug discovery where precise, targeted insights are essential.

Graph Neural Networks (GNNs) have shown promise in leveraging KG information for drug discovery, excelling in link prediction, and capturing biological relationships [22, 25, 37, 48]. However, training GNNs on large-scale KGs introduces substantial computational costs [1]. Additionally, GNNs struggle with inductive generalization, making it difficult to infer previously unobserved relationships for drugs or diseases [19], a drawback in drug discovery where new drugs and diseases continuously emerge. Large Language Models (LLMs) offer a promising alternative with strong



**Figure 1: Schematic representation of the predictive framework for unobserved interactions. (a) Problem formulation: We are given a network of observed interactions among known entities (drugs or diseases) and a broader biomedical network containing additional relationships between various entities (e.g., drugs, diseases, genes, etc.). The task is to predict unobserved interactions between a known entity and an emerging entity or two emerging entities. (b) Augmented KG: The observed interactions and biomedical network are integrated to create a richer representation for the prediction task.**

zero-shot generalization capabilities that enable adaptation to inductive tasks with minimal training [3, 4, 26]. Recent work has also shown that LLMs can be further adapted to specialized domains with KGs to improve their factual accuracy and reduce hallucinations [2, 3, 15, 42]. However, effectively extracting meaningful insights from knowledge graphs using LLMs is an ongoing challenge in the community [16, 36]. Recent work in drug discovery has proposed subgraph-based extraction methods to predict unobserved interactions from KGs, they often need to train an additional model and do not scale well beyond GNNs. Addressing these limitations is crucial for developing a scalable framework for drug discovery.

We introduce “K-Paths”, a novel retrieval framework designed to extract highly relevant entities and relationships from large biomedical KGs to aid in predicting unobserved drug-drug and drug-disease interactions. Unlike traditional KG retrieval methods, K-Paths generates structured, interpretable paths that can be directly used by LLMs, enabling efficient and accurate zero-shot reasoning. K-Paths is particularly valuable in drug discovery, where identifying such interactions can facilitate drug repurposing and safer treatment opportunities. Figure 1 illustrates the problem K-Paths addresses: We are given a network of observed interactions among known drugs or diseases and a broader biomedical network containing additional relationships between various entities (e.g., drugs, diseases, genes, etc.). Our goal is to predict unobserved interactions either between a known entity and an emerging entity—an entity whose interaction of interest has not been observed—or between two emerging entities, where neither entity has an observed interaction of interest. We focus on drug-disease and drug-drug

interactions because they play a critical role in drug discovery, clinical decision-making, and patient safety.

As shown in Figure 2, K-Paths operates in three steps. First, we construct an augmented KG by integrating observed interactions from the training set into the biomedical KG, enhancing its representation of interactions (as depicted in Figure 1). This enriched KG serves as the network for retrieving biologically meaningful connections. Next, we design a diversity-aware adaptation of Yen’s algorithm [45] to efficiently retrieve the  $K$  shortest loopless paths connecting entities in an interaction query. While Yen’s algorithm iteratively finds alternative shortest paths, K-Paths additionally prioritizes diverse and biologically meaningful connections, ensuring broader coverage rather than redundant variations of the shortest route. Finally, the retrieved diverse paths are transformed into natural language representations, enabling LLMs to reason over them and effectively predict interactions. Additionally, we show that these paths can be used to construct subgraphs, allowing GNN-based models to operate on a smaller, more focused graph and substantially reducing computational overhead.


To assess the impact of K-Paths, we evaluate its use in both zero-shot generative and supervised learning paradigms, focusing on drug repurposing and drug-drug interaction (DDI) analysis for emerging drugs and diseases. Our experiments on benchmark datasets demonstrate that K-Paths significantly enhances LLM reasoning in a zero-shot setting by providing relevant relational insights. Specifically, on a drug repurposing dataset, K-Paths improves Llama 8.1B Instruct’s F1-score by 12.45 points, and on an interaction severity task, it achieves a gain of 13.42. For Llama 70B Instruct, K-Paths provides comparable improvements, increasing the F1-score by 6.18 and 8.46 points, respectively, on the same tasks. In a supervised setting, K-Paths reduces the KG size by 90% and improves the training efficiency of EmerGNN [47], a state-of-the-art GNN model, without compromising model performance, showcasing its scalability. More importantly, the retrieved paths provide interpretable rationales for predicted interactions, enhancing explainability and offering valuable biological insights.

## 2 Related Work

### 2.1 Biomedical knowledge graphs

Biomedical knowledge graphs have been extensively used to study the complex relationships between drugs, diseases, and genes, leveraging these insights in drug discovery [22, 39, 46, 48]. These large-scale knowledge graphs have been curated for specialized purposes such as studying drug-disease interactions [21, 41], gene-drug interactions [40], and protein-protein interactions [17, 24]. In this work, we focus on drug-disease interactions and drug-drug interactions because they play a critical role in drug discovery, clinical decision-making, and patient safety.

A key limitation of biomedical knowledge graphs is that they can be incomplete in several ways. First, the knowledge graph may lack observed interactions between existing entities (e.g., drugs or diseases). Second, they may lack interactions between existing entities and emerging entities. We focus on predicting unobserved interactions among existing and emerging drugs or diseases, as



**Figure 2: K-Paths Overview.** (1) Given a query about the effect of an entity ( $u$ ) on another entity ( $v$ ), (2) K-Paths extracts reasoning paths from an augmented KG connecting ( $u$ ) and ( $v$ ). (3) These paths are filtered for diversity and (4a) transformed into natural language descriptions for LLM inference. (4b) The retrieved paths can also be used to construct a subgraph, enabling GNNs to leverage more manageable information for training and prediction.

well as interactions involving emerging drugs or diseases in large-scale biomedical knowledge graphs. These graphs are inherently incomplete, making such predictions particularly challenging.

## 2.2 LLMs for drug discovery

LLMs are becoming increasingly popular in many biomedical applications [9, 23, 28]. Several successful applications have been used as conversational agents for drug discovery [9], repurposing [23], and understanding drug molecules [28]. A key factor in their success is in-context learning [7], which allows them to process new information—such as examples and text—and reason effectively to generate accurate responses. This ability is particularly valuable for multi-hop reasoning, where models must integrate information across multiple steps or knowledge sources, such as biomedical knowledge graph paths, to form coherent and reliable conclusions [33]. Recent research has demonstrated that LLMs can leverage multi-hop reasoning to navigate knowledge graph paths and generate faithful answers to complex factual queries [32]. However, applying this approach to biomedical knowledge graphs for knowledge completion tasks remains under-explored despite its importance for real-world applications like drug discovery. In this work, we show that multi-hop reasoning over diverse paths from biomedical knowledge graphs significantly improves the zero-shot performance of off-the-shelf LLMs in predicting interactions between emerging drug entities.

K-Paths is related to a growing area of research at the intersection of retrieval augmented generation with graphs [15, 32, 43]. Recent works [15, 42, 43] constructs a knowledge graph from unstructured documents from the general domain with LLMs and reasons over it to produce the output. K-Paths uses a highly curated biomedical knowledge graph rather than constructing a knowledge graph on the fly to reason about drug entities and predict their interactions. Alternatively, studies like RoG [32] use an off-the-shelf knowledge graph such as Freebase to retrieve paths between entities and predict their relationship. However, this approach requires training an additional planning module to retrieve the paths and reason over all the paths, which is computationally expensive. In contrast, K-Paths uses a heuristic approach to retrieve paths, eliminating the

need for training and introducing a filtering step to diversify and reduce the number of paths needed for inference.

## 2.3 Graph neural networks for drug discovery

For supervised setting, graph neural networks have achieved strong performance in modeling the structure of the biomedical knowledge graph and predicting undiscovered interactions between entities [5, 30, 39, 47]. Several variants of graph convolutional networks have been used to address this problem. Furthermore, recent work has used external knowledge graphs such as Hetionet to learn richer representations for the entities [21, 39]. However, modeling large-scale biomedical knowledge is computationally expensive. To address this limitation, recent work introduces subgraph-based graph convolutional networks that extract fixed-sized subgraphs before passing them to the graph network. However, these models are designed for transductive settings. Unlike inductive setting, which is the goal of this work, transductive setting aims at predicting interactions between known entities. This property limits their ability to generalize to emerging entities— which is not ideal for drug discovery. In our work, we enhance the training knowledge graph using Hetionet and leverage K-Paths to retrieve diverse paths, enabling more efficient reasoning between existing and emerging entities while minimizing computational overhead.

Our work is closely related to EmerGNN [47] but differs in a few key ways. EmerGNN is a flow-based graph neural network that augments its knowledge graph with Hetionet and extracts paths from the knowledge graph to predict the interaction between emerging drugs. However, they train an additional model and use beam search to extract paths from the augmented knowledge graph. In contrast, K-Paths eliminates the need for training an additional model and provides diverse paths for predicting interactions between emerging drugs. Another limitation of EmerGNN is that their subgraph extraction is optimized for GNN models, limiting their applicability to other model architectures. In our work, our extracted paths are flexible and can be incorporated by both GNNs and LLMs, thus demonstrating their usability for both zero-shot and supervised learning. Furthermore, in Results Section5, we show K-Paths can be

integrated into EmerGNN and show improved performance compared to using the entire knowledge graph. Finally, our method significantly improves zero-shot performance with LLMs without updating model parameters.

### 3 Approach

#### 3.1 Problem Definition

Building on the problem illustrated in Figure 1, we aim to predict unobserved interactions in an inductive reasoning setup, as described in Zhang et al. [47]. These interactions can involve:

- A known entity (e.g., a well-studied drug or disease with some observed interactions) and an emerging entity (e.g., a drug or disease whose interactions of interest have not been observed), or
- Two emerging entities.

The unobserved interactions may include drug-drug interactions or drug-disease interactions.

Formally, we define a knowledge graph  $\mathcal{G} = \{(u, r, v) \mid u, v \in \mathcal{E}, r \in \mathcal{R}\}$  where  $u, v \in \mathcal{E}$  represent biomedical entities (e.g., drugs, diseases, genes) and  $r \in \mathcal{R}$  denotes a relation type. These relation types include known drug-drug and drug-disease interactions (observed interactions) and a broader biomedical network with relationships like drug-gene or gene-gene interactions.

Given two query entities  $u$  and  $v$ , our goal is to infer their interaction type, which is framed as predicting the presence and type of relation  $r$  between  $u$  and  $v$ . We define a computational model  $\phi(\mathcal{G})$  to predict these interactions under both zero-shot generative and supervised settings. Specifically, we leverage LLMs for reasoning-based inference and GNNs for interaction prediction.

#### 3.2 K-Paths Framework

We introduce *K-Paths*, a framework for predicting the interaction between entities  $u$  and  $v$ . K-Paths comprises three key components:

- (1) An *Augmented KG*: This module constructs a knowledge graph  $\mathcal{G}$  by integrating known drug-drug or drug-disease interactions with a broader biomedical KG. This integration incorporates additional entities such as genes and their known relationships (e.g., drug-gene or gene-gene interactions).
- (2) A *Diverse Path Retrieval module*: This module employs a novel path retrieval algorithm to retrieve a diverse set of relevant reasoning paths connecting the query entities  $u$  and  $v$  from the augmented KG  $\mathcal{G}$ .
- (3) A *Path Integration module*: This module processes the retrieved query-specific paths for interaction prediction. For LLM-based reasoning and interaction inference, the paths are transformed into natural language and appended to the interaction query prompt. For GNN-based interaction prediction, the paths are reconstructed into query-specific subgraphs.

The overall K-Paths framework is illustrated in Figure 2.

#### 3.3 Augmented KG

Following prior work [39, 46, 47], we define the *augmented KG* as our knowledge graph  $\mathcal{G}$ , constructed by integrating:

- (1) Observed interactions (e.g., drug-drug and drug-disease) from the training set.
- (2) Hetionet, a biomedical knowledge graph containing biological entities (e.g., genes, proteins, pathways) and their relationships (e.g., drug-gene, gene-gene, protein-protein interactions) [21].

Since Hetionet is incomplete, incorporating known interactions from the training set enhances coverage and helps build a more comprehensive augmented KG. However, interactions involving emerging entities remain missing in this graph. To address this, we leverage existing relationships within the augmented KG to infer these unobserved interactions. Additionally, following [47], we incorporate inverse relations to account for the directed nature of the augmented KG, ensuring bidirectional information flow.

The augmented KG  $\mathcal{G}$  serves as the structured knowledge graph for all subsequent tasks.

---

**Algorithm 1:** Filtering algorithm to remove redundant retrieved paths.

---

**Input:** A set of paths  $P = \{p_1, p_2, \dots, p_K\}$ , where each path  $p$  is described by

$R(p) = (r_1, r_2, \dots, r_l)$  (sequence of relations) and  $\mathcal{E}(p) = (e_1, e_2, \dots, e_m)$  (sequence of entities).

**Output:** A subset  $P' \subseteq P$  with redundant paths removed.

Initialize  $P' \leftarrow \emptyset$ ;

**foreach** path  $p \in P$  **do**

Let  $R(p) = (r_1, r_2, \dots, r_l)$  be the relation sequence of  $p$ ;  
 Let  $l = |R(p)|$  (the length of the relation sequence);  
**if**  $\nexists q \in P'$  such that  $R(q) = R(p)$  **and**  $|R(q)| = l$  **then**  
 $P' \leftarrow P' \cup \{p\}$ ;

**return**  $P'$

---

#### 3.4 Diverse Path Retrieval Module

The path retrieval module is a key component of our framework. It provides the downstream computational model with highly relevant yet manageable information from our augmented KG  $\mathcal{G}$ .

Our diverse path retrieval algorithm retrieves a set of  $K$  shortest diverse paths between two entities,  $\{u, v\}$ , from  $\mathcal{G}$  using Yen’s algorithm [45]. We prioritize shortest paths for several reasons. Shorter paths capture stronger, more interpretable relationships, while longer paths introduce noise and uncertainty [6, 29]. Finally, empirical studies on biomedical KGs further show that meaningful interactions typically occur within a few hops [20, 48].

Yen’s algorithm extends Dijkstra’s algorithm [11] by iteratively computing shortest paths while temporarily excluding specific edges, thus generating progressively longer, loop-free alternatives. The output from this process contains redundant paths. Therefore, we introduce a filtering algorithm (Algorithm 1) to remove these redundancies. Our filtering algorithm eliminates paths with duplicate relation sequences of the same path length. This filtering step results in a diverse set of paths, which are passed to the next module in our framework.

In cases where only one of  $\{u, v\}$  exists in  $\mathcal{G}$ , we retrieve its immediate neighbors and their connecting relationships, applying

the same filtering algorithm. This provides valuable context even when a complete path between two entities cannot be established. If neither entity exists in  $\mathcal{G}$ , no information is retrieved.

### 3.5 Path Integration Module

This module integrates the retrieved diverse paths to predict interactions between the query entities. We explore two distinct approaches: LLM-based reasoning and GNN-based prediction.

**LLM Reasoning** We convert the entities and relations from the diverse paths into natural language using predefined dictionaries. These dictionaries map entities and relations to their respective types and textual representations. To improve clarity, we append entity type descriptors in parentheses after each entity.

For example, as illustrated in Figure 2, consider the path:

$$p_1 : u \rightarrow r_1 \rightarrow a_1 \rightarrow r_2 \rightarrow v$$

representing the relationship between *Quetiapine* and *Bipolar disorder*. This path is transformed into the natural language description:

*Quetiapine binds HTR1A (gene) and HTR1A (gene) associates with Bipolar disorder.*

Following [47], if the retrieved relation belongs to an inverse relation category, we convert it into passive voice. For instance, the relation:

*(Disease) downregulates (Gene)*

is converted into:

*(Gene) is downregulated by (Disease).*

This explicit type mapping helps the LLM understand the semantic roles of each entity, even if it is unfamiliar with domain-specific entities like "HTR1A". This conversion process is applied to all  $K$  retrieved paths. In the zero-shot setting, these textualized paths are appended to the original query, providing contextual information for the LLM to perform inference. In the supervised setting, we can fine-tune the LLM using these textualized paths as training data. Furthermore, representing the retrieved paths in natural language enhances the explainability of the LLM's predictions.

**GNN Interaction Prediction** For GNN-based prediction, instead of directly inputting the large augmented KG into the GNN, we use the diverse paths to construct smaller, query-specific subgraphs. This approach significantly reduces the computational complexity and allows GNN to focus on the most relevant information. During training, the GNN learns entity-specific representation by aggregating information from known drug-drug or drug-disease interactions and their corresponding query-specific subgraphs. These learned representations are then used to predict the type of interaction between entity pairs. During testing, we extend the learned representation space by incorporating new test nodes and their corresponding query-specific subgraphs. This allows us to evaluate the model's ability to accurately predict unobserved interactions using this extended graph in a supervised inductive setting.

## 4 Experiments

In this section, we aim to answer the following research questions:

**RQ1:** Can LLMs accurately predict interaction *types*, *severities*, or *indications* by reasoning over multi-hop knowledge graph paths provided as context in a zero-shot setting?

**RQ2:** How do path selection strategies (e.g., shortest path, diverse path selection) and the number of reasoning paths ( $K$ ) influence LLM performance in interaction prediction tasks?

**RQ3:** How do subgraphs derived from the K-Paths framework impact the performance of LLMs and GNNs in a supervised setting?

### 4.1 Datasets

**Evaluation Datasets:** Following previous work, we conducted experiments in an inductive setting to assess the model's generalization to unseen entities. In this setting, the training set includes interactions only between entities in the training set, the validation set contains interactions where at least one entity appears only in the validation set or interactions exclusively within it, and the test set follows the same rule for test entities. This setup enables evaluation of the model's ability to predict unobserved interactions involving both known and emerging entities, as well as interactions between emerging entities.

We used three datasets with different task objectives: DDInter [44], PharmacotherapyDB (v1.0) [20], and DrugBank [41]. For DrugBank, we applied the inductive split from [13], while for DDInter, we created train, validation, and test sets following the described inductive split. Due to its smaller size, PharmacotherapyDB was divided into training and test sets in a similar inductive setting. Table 1 provides detailed statistics, including the number of specific interaction types.

**External Knowledge Base:** Hetionet is a heterogeneous biomedical network curated from 29 databases. It includes various biomedical entities such as compounds, genes, diseases, etc. Following [46], the processed version used in this work includes 33,765 nodes across 11 types and 1,690,693 edges spanning 23 relation types.

### 4.2 Baselines

We compare the K-Paths framework with the following baselines:

**4.2.1 LLM-based Baselines:** Here, we evaluated the impact of K-Paths on LLM reasoning in zero-shot and supervised settings.

- **Reasoning based on internal knowledge (Base):** The LLM uses only its internalized knowledge to infer interactions and relationships.
- **Reasoning based on textual definitions (Definitions):** The LLM leverages textual definitions of drugs and diseases from external resources, such as DrugBank<sup>2</sup> and the Disease Ontology<sup>3</sup>, to infer interactions and relationships independent of the knowledge graph's structure.

**4.2.2 GNN-based Baselines:** Here, we evaluated the impact of K-Paths on GNNs in a supervised setting only.

- **Complete Graph-based Prediction (Complete KG):** The Graph Neural Network (GNN) uses the entire augmented KG to predict interactions, considering all entities and relationships.

<sup>2</sup><https://go.drugbank.com/>

<sup>3</sup><https://disease-ontology.org/>

Dataset	Entities	Categories	Example
DDInter	1,689 drugs	3 interaction severity levels	Severity: Major (DrugX + DrugY)
PharmacotherapyDB	601 drugs 97 diseases	3 indications	DrugX treats DiseaseY
Drugbank	1,710 drugs	86 metabolic interaction levels	DrugX decreases excretion rate of DrugY

**Table 1: Overview of the datasets and tasks studied.**

### 4.3 Implementation details

We provide the details for K-Paths implementation for all our experiments with different LLMs and GNNs. For further details on prompting strategies, training configurations, and hyperparameters, see Appendix A. During path retrieval, we limit the maximum path length to 3 as longer paths tend to be more susceptible to noise and less likely to represent meaningful, interpretable relationships. We assume there is no direct link between the query entities whose interaction we aim to predict, and the model must infer the interaction type by reasoning over existing facts in the knowledge graph. To prevent data leakage, we explicitly check and remove direct interaction links between entities during training and verify their absence in the test set. For all experiments across datasets, we set  $K = 10$  retrieved paths per query.

For LLM reasoning, we employ Llama-3.1-8B-Instruct [14] and Llama-3.1-70B-Instruct [14] as our primary inference models, leveraging their instruction-following capabilities. In zero-shot settings, we utilize direct prompting to evaluate their reasoning ability. In supervised settings, we fine-tuned Llama-3.1-8B-Instruct using QLoRA, a lightweight and efficient fine-tuning approach. In both these experiments, we generate the output with a greedy decoding. For GNN architectures, we use Relational Graph Convolutional Networks (RGCN) because of their ability to handle relational data, which aligns with our task. Additionally, we adopt EmerGNN’s backbone architecture, as it is the current state-of-the-art inductive graph-based model for drug-drug interaction prediction tasks.

### 4.4 Evaluation

Following [47], for all the experiments, we report the accuracy, macro averaged F1-score, and Cohen’s Kappa for the multi-class classification task. Since LLMs generate open-ended responses, we first parse the response using regular expression and map it to one of the labels in the dataset. If we cannot map the response to one of the labels in the dataset, we assign the prediction to the majority class from the training set. We also report the same evaluation metrics for GNN experiments.

## 5 Results

### 5.1 K-Paths improves LLM Reasoning in a Zero-Shot Setting

We evaluate LLMs’ reasoning capabilities for interaction prediction across three zero-shot scenarios with varying context: (1) Base, where the LLM relies solely on its internal knowledge; (2) Definitions, where textual definitions of drugs and diseases are provided; and (3) K-Paths, where the LLM is provided with diverse paths retrieved by our K-Paths framework.

Table 2 presents results for Llama 3.1 8B and 70B on the DDInter, PharmacotherapyDB, and DrugBank datasets. Across all datasets, LLMs significantly benefit from the diverse reasoning paths, outperforming both the Base and Definitions settings. On DDInter, K-Paths boosts the F1-score by 13.42 for Llama 3.1 8B and 6.18 for Llama 3.1 70B, compared to the Definitions setting. Similarly, on PharmacotherapyDB, inference with K-Paths leads to F1-score improvements of 12.45 (Llama 3.1 8B) and 8.46 (Llama 3.1 70B). In some cases, Definitions slightly improve performance over Base or even degrade it, but they consistently fall short of the substantial gains achieved with K-Paths. This difference likely stems from the nature of the information provided. K-paths offer structured, contextualized knowledge, showing how entities are related. Definitions, while informative, provide declarative knowledge without this crucial relational context, making it harder for LLMs to reason about interactions effectively. Performance on the DrugBank task, which involves 86 interaction types, also highlights the necessity of structured reasoning. For both models, DrugBank’s Base F1-scores hover around 1%, but with K-Paths, they improve to approximately 40%, emphasizing the importance of structured external knowledge in such complex tasks.

Model scaling (70B vs. 8B) demonstrates better reasoning ability with consistent performance improvements, but the gains diminish when external knowledge is provided. This suggests that high-quality external knowledge may reduce the reliance on larger parameter models. For example, on DDInter, the 8B model’s F1-Score was slightly higher. These findings highlight that LLMs benefit significantly from structured reasoning paths in zero-shot settings.

### 5.2 K-Paths Improves LLM Responses

To complement our quantitative evaluation in Section 5.1, we conducted a qualitative analysis examining how the different forms of external knowledge—definitions and K-paths influence LLM responses. Table 3 presents two case studies from PharmacotherapyDB and DDInter, comparing the model’s predictions under different knowledge augmentation conditions. We make two key observations. (1) Without external knowledge, the Base model often predicts incorrectly, demonstrating insufficient domain knowledge. In the PharmacotherapyDB example, although the Definition of *Vincristine* mentions its use in cancer treatments, the model failed to infer its applicability to *Muscle Cancer*. However, introducing diverse reasoning paths from K-Paths improved the LLM’s predictions. This suggests that simply providing factual information (definitions) without explicit relational information is insufficient for correct reasoning in interaction prediction.

(2) Diverse retrieved paths enable the model to connect relevant entities and their relationships, facilitating more accurate and contextually relevant answers. For instance, in the DDInter example, when K-Paths was incorporated, the model correctly predicted a “Major” interaction between *Ritonavir* and *Leflunomide*, identifying *Neutropenia* as a possible side effect. This is crucial, as *Neutropenia* is a potentially life-threatening condition. A “Moderate” misclassification could have severe safety implications, stressing the importance of high-quality reasoning paths for model reliability, especially in high-stakes medical contexts where inadequate therapy selection may lead to patient harm. In summary, the LLM responses in the

Model	Setting	DDInter			PharmacotherapyDB			DrugBank		
		Accuracy	F1	Kappa	Accuracy	F1	Kappa	Accuracy	F1	Kappa
Llama 3.1 8B Instruct	Base	69.09	33.34	4.37	<u>57.94</u>	<u>51.91</u>	<u>35.18</u>	31.36	0.65	0.87
	Defintions	<u>70.43</u>	<u>33.46</u>	<u>5.51</u>	57.54	51.70	34.38	<u>31.63</u>	<u>0.68</u>	<u>0.95</u>
	K-Paths	<b>75.93</b>	<b>46.76</b>	<b>36.99</b>	<b>69.44</b>	<b>64.36</b>	<b>51.34</b>	<b>55.54</b>	<b>40.46</b>	<b>45.58</b>
Llama 3.1 70B Instruct	Base	70.51	<u>40.01</u>	<u>19.07</u>	60.71	59.00	39.38	<u>31.32</u>	<u>1.35</u>	<u>3.88</u>
	Definitions	<u>71.61</u>	37.07	12.98	<u>62.30</u>	<u>61.14</u>	<u>42.30</u>	30.48	1.03	1.84
	K-Paths	<b>78.01</b>	<b>46.19</b>	<b>35.33</b>	<b>71.03</b>	<b>67.46</b>	<b>54.66</b>	<b>57.72</b>	<b>46.91</b>	<b>49.19</b>

Table 2: Performance comparison of Llama 3.1 models on zero-shot reasoning tasks. Bold indicates the best performance, while underlined denotes the second-best performance. K-Paths improves domain-specific reasoning in zero-shot setting.

	PharmacotherapyDB	DDinter
Query	Determine the possible effect of using <i>Vincristine</i> (Drug) for <i>Muscle cancer</i> (Disease).	Determine the severity of interaction when <i>Ritonavir</i> (Drug 1) and <i>Leftunomide</i> (Drug 2) are taken together.
Answer	Disease Modifying	Major
Definitions	<i>Vincristine</i> is an antitumor that treats leukemia, lymphoma, Hodgkin’s disease, and other blood disorders. <i>Muscle cancer</i> is a musculoskeletal system cancer located in the muscle.	<i>Ritonavir</i> , an HIV protease inhibitor, boosts other protease inhibitors’ effectiveness and is used in some HCV therapies. As a CYP3A inhibitor, it increases drug concentrations. <i>Leftunomide</i> is a pyrimidine synthesis inhibitor belonging to the disease-modifying antirheumatic drugs chemically and pharmacologically very heterogeneous.
K-Paths	<i>Vincristine</i> treats Kidney Cancer (Disease) and Kidney Cancer (Disease) resembles <i>Muscle Cancer</i> . <i>Vincristine</i> downregulates <i>TP53</i> (Gene) and <i>TP53</i> (Gene) is associated with Muscle Cancer.	<i>Ritonavir</i> binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by <i>Leftunomide</i> <i>Ritonavir</i> causes Neutropenia (Side Effect), and Neutropenia (Side Effect) is caused by <i>Leftunomide</i>
LLM Only	Non Indications	Moderate
LLM+Definitions	Non Indications	Moderate
LLM+K-Paths	Disease Modifying	Major

Table 3: Comparison of LLM responses based on external knowledge type. K-Paths allows for explainable inference.

LLM+K-Paths setting demonstrate that while Definitions provide some information about query entities, structured, diverse KG paths are essential for effective contextualization and improved zero-shot performance.

### 5.3 Influence of Path Selection Strategies on LLM Performance

We conduct an ablation study using Llama 3.1 8B on the validation set to investigate the impact of different path selection strategies and the number of retrieved paths ( $K$ ) on LLM performance in interaction prediction. Specifically, we compared LLM performance using the “Base” setting ( $K = 0$ ), diverse paths ( $K = 1, 5, 10, 15, 20$  from our K-Paths framework), and shortest paths (without diversity filtering).

Results in Table 3 show that adding diverse reasoning paths significantly improves performance. On DDInter, F1-scores increase from 12.66% ( $K = 0$ ) to 46.73% ( $K = 10$ ), and on DrugBank, they increase from 0.59% ( $K = 0$ ) to 43.35% ( $K = 10$ ). However, performance gains diminish beyond  $K = 10$ , suggesting that excessively long paths introduce redundancy or noise. Furthermore, K-Paths outperforms shortest-path selection (without diversity filtering). Removing our filtering algorithm results in the degradation of the F1-score by 6.99% on DDInter and 4.32% on DrugBank, demonstrating the importance of diverse path retrieval for improved performance.

### 5.4 Impact of K-Paths Derived Subgraphs on Supervised LLM and GNN Performance

We evaluate the influence of subgraphs derived from retrieved paths on supervised learning for LLMs and GNNs.

**LLM Performance:** We fine-tuned Llama 3.1 8B Instruct using K-Paths and textual definitions. As shown in Table 4, fine-tuned LLMs perform comparably regardless of the training source, indicating their ability to integrate both structured and unstructured knowledge when supervision is provided. However, we further observe that definitions often outperform K-Paths, likely because they provide a more direct and semantically rich signal that is easier to learn; in contrast, in the zero-shot setting (Section 5.1), K-Paths provide more useful relational cues.

**GNN Performance:** We compared GNN models trained on the full knowledge graph (Complete KG) against those trained on the subgraphs constructed from the K-Paths framework. Table 4 shows that with K-Paths, we achieve comparable accuracy to using the Complete KG despite being approximately 90% smaller. This reinforces that smaller, task-specific graphs enhance efficiency without significant performance loss. For example, on DDInter, EmerGNN achieves nearly identical performance using K-Paths (F1: 68.85%) compared to Complete KG (F1: 68.00%), suggesting that a targeted subgraph retains essential knowledge while significantly improving efficiency. RGCN benefits from K-Paths, with F1 increasing




Figure 3: Influence of path selection strategies on Llama 3.1 8B. Diverse paths are essential for performance improvement.

Model	Setting	DDInter			PharmacotherapyDB			DrugBank		
		Accuracy	F1	Kappa	Accuracy	F1	Kappa	Accuracy	F1	Kappa
<b>LLM-Based Models</b>										
QLoRA-Llama	Definitions	82.36	67.96	53.64	<b>81.75</b>	<b>79.91</b>	<b>71.84</b>	<b>73.22</b>	<b>68.15</b>	<b>67.26</b>
QLoRA-Llama	K-Paths	80.55	<u>68.63</u>	57.85	<u>78.57</u>	<u>76.71</u>	<u>66.68</u>	<u>71.83</u>	<u>65.57</u>	<u>65.63</u>
<b>Graph-Based Models (GNNs)</b>										
EmerGNN	Complete KG	84.26	68.00	<u>58.92</u>	71.43	68.41	55.38	71.04	59.42	65.14
EmerGNN	K-Paths	<b>84.53</b>	<b>68.85</b>	<b>58.91</b>	71.03	68.12	54.10	68.98	59.06	62.54
RGCN	Complete KG	72.01	51.47	31.38	61.11	60.08	41.12	29.98	15.49	20.88
RGCN	K-Paths	73.32	52.12	32.70	66.82	61.74	39.25	31.70	17.51	23.14

Table 4: Performance of various models across datasets in a supervised setting. Bold indicates the best performance, and underlined denotes the second-best. LLMs leverage both knowledge types effectively with supervision, and K-Paths enhance GNN efficiency without significant performance loss.

Dataset	Before Retrieval (Complete KG)					After Retrieval (K-Paths)				
	#Nodes	#Relations	#Triplets	Sec/Epoch	{EmerGNN, RGCN}	#Nodes	#Relations	#Triplets	Sec/Epoch	{EmerGNN, RGCN}
<b>DDInter</b>	35,107	26	1,763,596	{606.24s, 5.78s}	4,723	18	113,933	{102.21s, 1.18s}		
<b>PharmacotherapyDB</b>	34,412	26	1,691,829	{20.83s, 2.41s}	3,307	23	11,905	{2.95s, 0.12s}		
<b>DrugBank</b>	35,103	109	1,789,976	{1011.86s, 11.41s}	6,335	101	184,273	{146.98s, 3.56s}		

Table 5: Augmented KG Statistics: K-Paths Improves Training Efficiency.

from 51.47% (Complete KG) to 52.12% (K-Paths) on DDInter and from 15.49% to 17.51% on DrugBank. This highlights the advantage of a more focused graph structure for such models. This result is consistent in the transductive setting shown in the Appendix D.2.

**Efficiency Analysis:** Table 5 analyzes the augmented network’s statistics before and after K-Paths subgraph retrieval. The results clearly demonstrate that this retrieval process significantly reduces the number of nodes, relations, and triplets, leading to faster training times and reduced memory usage. For instance, on DrugBank, the number of nodes reduces from 35,103 to 6,335, the number of triplets decreases from 1,789,976 to 184,273, and the time per epoch for EmerGNN drops from 1011.86s to 146.98s. Similarly, for DDInter, the reduction in graph size leads to a considerable speedup, with EmerGNN’s time per epoch decreasing from 606.24s to 102.21s. We

also show the important relations retained by K-Paths in the Appendix D.4. These results highlight that K-Paths improves training efficiency without compromising model performance, reinforcing the scalability of our approach.

**LLM vs. GNN Performance:** Finally, we observe that supervised fine-tuning enables LLMs to outperform GNNs on most datasets, suggesting that supervised LLMs can effectively leverage multiple structured and unstructured modalities and sometimes even surpass GNNs trained solely on relational graphs.

## 6 Conclusion

This work introduces *K-Paths*, a novel path retrieval framework that extracts relevant and diverse reasoning paths from large biomedical knowledge graphs. K-Paths enables LLMs to effectively reason

about and predict unobserved interactions between emerging drugs and diseases. By constructing concise subgraphs, K-Paths also significantly reduce the computational burden of training GNNs on large-scale KGs, achieving up to a 90% reduction in graph size without significant loss in performance. While demonstrated here for predicting drug-drug and drug-disease interactions, we propose that K-Paths is potentially generalizable to other biomedical tasks, such as protein-protein interaction prediction. We acknowledge a key limitation: K-Paths relies on interaction types learned from existing knowledge. This may restrict its ability to identify novel interactions not yet represented in the biomedical network or training data. Furthermore, a knowledge graph with sparse or biased representation of entities could negatively impact K-Paths' performance when predicting interactions involving such entities. Despite these limitations, K-Paths provides valuable insights into biomedical interactions by enhancing model explainability and extracting biologically meaningful reasoning paths. We believe this work lays a foundation for future exploration of integrating LLMs and KGs in biomedical applications, paving the way for more efficient and interpretable solutions in drug discovery and other related fields.

## Acknowledgements

This material is based in part upon work supported by the National Science Foundation under Grant No. RISE-2425380. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. Disclosure: Stephen Bach is an advisor to Snorkel AI, a company that provides software and services for data-centric artificial intelligence.

## References

- [1] Hussein Abdallah, Waleed Afandi, Panos Kalnis, and Essam Mansour. 2024. Task-Oriented GNNs Training on Large Knowledge Graphs for Accurate and Efficient Modeling. *arXiv preprint arXiv:2403.05752* (2024).
- [2] Tassallah Abdullahi, Laura Mercurio, Ritambhara Singh, and Carsten Eickhoff. 2024. Retrieval-Based Diagnostic Decision Support: Mixed Methods Study. *JMIR Medical Informatics* 12 (2024), e50209.
- [3] Tassallah Abdullahi, Ritambhara Singh, and Carsten Eickhoff. 2024. Retrieval augmented zero-shot text classification. In *Proceedings of the 2024 ACM SIGIR international conference on theory of information retrieval*. 195–203.
- [4] Tassallah Abdullahi, Ritambhara Singh, Carsten Eickhoff, et al. 2024. Learning to make rare and complex diagnoses with generative AI assistance: qualitative study of popular large language models. *JMIR Medical Education* 10, 1 (2024), e51391.
- [5] Mohammad Hussain Al-Rabeah and Amir Lakizadeh. 2022. Prediction of drug-drug interaction events using graph neural networks based feature extraction. *Scientific Reports* 12, 1 (2022), 15590.
- [6] Albert-Laszlo Barabasi and Zoltan N Oltvai. 2004. Network biology: understanding the cell's functional organization. *Nature reviews genetics* 5, 2 (2004), 101–113.
- [7] Tom Brown, Benjamin Mann, Nick Ryder, Melanie Subbiah, Jared D Kaplan, Prafulla Dhariwal, Arvind Neelakantan, Pranav Shyam, Girish Sastry, Amanda Askell, et al. 2020. Language models are few-shot learners. *Advances in neural information processing systems* 33 (2020), 1877–1901.
- [8] Payal Chandak, Kexin Huang, and Marinka Zitnik. 2023. Building a knowledge graph to enable precision medicine. *Scientific Data* 10, 1 (2023), 67.
- [9] Juan Manuel Zambrano Chaves, Eric Wang, Tao Tu, Eeshit Dhaval Vaishnav, Byron Lee, S. Sara Mahdavi, Christopher Semturs, David Fleet, Vivek Natarajan, and Shekoofeh Azizi. 2024. Tx-LLM: A Large Language Model for Therapeutics. *arXiv:2406.06316* [cs.CL] <https://arxiv.org/abs/2406.06316>
- [10] Susan B. Davidson, Chris Overton, and Peter Buneman. 1995. Challenges in integrating biological data sources. *Journal of Computational Biology* 2, 4 (1995), 557–572.
- [11] Edsger W Dijkstra. 1959. A note on two problems in connexion with graphs. *Numerische mathematik* 1, 1 (1959), 269–271.
- [12] Joseph A DiMasi, Ronald W Hansen, and Henry G Grabowski. 2003. The price of innovation: new estimates of drug development costs. *Journal of health economics* 22, 2 (2003), 151–185.
- [13] Haotong Du, Quanming Yao, Juzheng Zhang, Yang Liu, and Zhen Wang. 2024. Customized Subgraph Selection and Encoding for Drug-drug Interaction Prediction. *arXiv preprint arXiv:2411.01535* (2024).
- [14] Abhimanyu Dubey, Abhinav Jauhri, Abhinav Pandey, Abhishek Kadian, Ahmad Al-Dahle, Aiesha Letman, Akhil Mathur, Alan Schelten, Amy Yang, Angela Fan, et al. 2024. The llama 3 herd of models. *arXiv preprint arXiv:2407.21783* (2024).
- [15] Darren Edge, Ha Trinh, Newman Cheng, Joshua Bradley, Alex Chao, Apurva Mody, Steven Truitt, and Jonathan Larson. 2024. From Local to Global: A Graph RAG Approach to Query-Focused Summarization. *arXiv:2404.16130* [cs.CL] <https://arxiv.org/abs/2404.16130>
- [16] Bahare Fatemi, Jonathan Halcrow, and Bryan Perozzi. 2023. Talk like a graph: Encoding graphs for large language models. *arXiv preprint arXiv:2310.04560* (2023).
- [17] Ziqi Gao, Chenran Jiang, Jiawen Zhang, Xiaosen Jiang, Lanqing Li, Peilin Zhao, Huanming Yang, Yong Huang, and Jia Li. 2023. Hierarchical graph learning for protein-protein interaction. *Nature Communications* 14, 1 (2023), 1093.
- [18] Vladimir Gligorijević and Nataša Pržulj. 2015. Methods for biological data integration: perspectives and challenges. *Journal of the Royal Society Interface* 12, 112 (2015), 20150571.
- [19] Will Hamilton, Zhitao Ying, and Jure Leskovec. 2017. Inductive representation learning on large graphs. *Advances in neural information processing systems* 30 (2017).
- [20] Daniel Himmelstein, Pouya Khankhanian, Christine S Hessler, Ari J Green, and Sergio Baranzini. 2016. PharmacotherapyDB 1.0: the open catalog of drug therapies for disease. *Figshare*. DOI: <https://doi.org/10.6084/m9.figshare.3103054> (2016).
- [21] Daniel Scott Himmelstein, Antoine Lizée, Christine Hessler, Leo Brueggeman, Sabrina L Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, and Sergio E Baranzini. 2017. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. *eLife* 6 (sep 2017), e26726. doi:10.7554/eLife.26726
- [22] Kexin Huang, Payal Chandak, Qianwen Wang, Shreyas Havaldar, Akhil Vaid, Jure Leskovec, Girish N Nadkarni, Benjamin S Glicksberg, Nils Gehlenborg, and Marinka Zitnik. 2024. A foundation model for clinician-centered drug repurposing. *Nature Medicine* (2024), 1–13.
- [23] Yoshitaka Inoue, Tianci Song, and Tianfan Fu. 2024. DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning. *arXiv:2408.13378* [cs.AI] <https://arxiv.org/abs/2408.13378>
- [24] Kanchan Jha, Sriparna Saha, and Hiteshi Singh. 2022. Prediction of protein-protein interaction using graph neural networks. *Scientific Reports* 12, 1 (2022), 8360.
- [25] Thomas Kipf and Max Welling. 2016. Semi-Supervised Classification with Graph Convolutional Networks. *ArXiv abs/1609.02907* (2016). <https://api.semanticscholar.org/CorpusID:3144218>
- [26] Takeshi Kojima, Shixiang Shane Gu, Machel Reid, Yutaka Matsuo, and Yusuke Iwasawa. 2022. Large language models are zero-shot reasoners. *Advances in neural information processing systems* 35 (2022), 22199–22213.
- [27] Michael Kuhn, Christian von Mering, Monica Campillos, Lars Juhl Jensen, and Peer Bork. 2007. STITCH: interaction networks of chemicals and proteins. *Nucleic acids research* 36, suppl\_1 (2007), D684–D688.
- [28] Youwei Liang, Ruiyi Zhang, Li Zhang, and Pengtao Xie. 2023. DrugChat: Towards Enabling ChatGPT-Like Capabilities on Drug Molecule Graphs. *arXiv:2309.03907* [q-bio.BM] <https://arxiv.org/abs/2309.03907>
- [29] David Liben-Nowell and Jon Kleinberg. 2003. The link prediction problem for social networks. In *Proceedings of the twelfth international conference on Information and knowledge management*. 556–559.
- [30] Xuan Lin, Zhe Quan, Zhi-Jie Wang, Tengfei Ma, and Xiangxiang Zeng. 2020. KGNN: Knowledge Graph Neural Network for Drug-Drug Interaction Prediction.. In *IJCAI*, Vol. 380. 2739–2745.
- [31] Yinhan Liu, Myle Ott, Naman Goyal, Jingfei Du, Mandar Joshi, Danqi Chen, Omer Levy, Mike Lewis, Luke Zettlemoyer, and Veselin Stoyanov. 2019. RoBERTa: A Robustly Optimized BERT Pretraining Approach. *arXiv:1907.11692* [cs.CL] <https://arxiv.org/abs/1907.11692>
- [32] Linhao Luo, Yuan-Fang Li, Gholamreza Haffari, and Shirui Pan. 2024. Reasoning on Graphs: Faithful and Interpretable Large Language Model Reasoning. *arXiv:2310.01061* [cs.CL] <https://arxiv.org/abs/2310.01061>
- [33] Costas Mavromatis and George Karypis. 2024. GNN-RAG: Graph Neural Retrieval for Large Language Model Reasoning. *arXiv:2405.20139* [cs.CL] <https://arxiv.org/abs/2405.20139>
- [34] Steven M Paul, Daniel S Mytelka, Christopher T Dunwiddie, Charles C Persinger, Bernard H Munos, Stacy R Lindborg, and Aaron L Schacht. 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature reviews Drug discovery* 9, 3 (2010), 203–214.
- [35] Ciyuan Peng, Feng Xia, Mehdi Naseriparsa, and Francesco Osborne. 2023. Knowledge graphs: Opportunities and challenges. *Artificial Intelligence Review* 56, 11 (2023), 13071–13102.

- [36] Bryan Perozzi, Bahare Fatemi, Dustin Zelle, Anton Tsitsulin, Mehran Kazemi, Rami Al-Rfou, and Jonathan Halcrow. 2024. Let your graph do the talking: Encoding structured data for llms. *arXiv preprint arXiv:2402.05862* (2024).
- [37] M. Schlichtkrull, Thomas Kipf, Peter Bloem, Rianne van den Berg, Ivan Titov, and Max Welling. 2017. Modeling Relational Data with Graph Convolutional Networks. In *Extended Semantic Web Conference*. Springer, New York, NY, USA, 593–607. <https://api.semanticscholar.org/CorpusID:5458500>
- [38] Jessica Vamathevan, Dominic Clark, Paul Czodrowski, Ian Dunham, Edgardo Ferran, George Lee, Bin Li, Anant Madabhushi, Parantu Shah, Michaela Spitzer, et al. 2019. Applications of machine learning in drug discovery and development. *Nature reviews Drug discovery* 18, 6 (2019), 463–477.
- [39] Yaqing Wang, Zaifei Yang, and Quanming Yao. 2024. Accurate and interpretable drug–drug interaction prediction enabled by knowledge subgraph learning. *Communications Medicine* 4, 1 (2024), 59.
- [40] Michelle Whirl-Carrillo, Rachel Huddart, Li Gong, Katrin Sangkuhl, Caroline F. Thorn, Ryan Whaley, and Teri E. Klein. 2021. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. *Clinical Pharmacology & Therapeutics* 110, 3 (July 2021), 563–572. doi:10.1002/cpt.2350
- [41] David S Wishart, Yannick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, et al. 2018. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic acids research* 46, D1 (2018), D1074–D1082.
- [42] Junde Wu, Jiayuan Zhu, Yunli Qi, Jingkun Chen, Min Xu, Filippo Menolascina, and Vicente Grau. 2024. Medical graph rag: Towards safe medical large language model via graph retrieval-augmented generation. *arXiv preprint arXiv:2408.04187* (2024).
- [43] Guangzhi Xiong, Qiao Jin, Zhiyong Lu, and Aidong Zhang. 2024. Benchmarking Retrieval-Augmented Generation for Medicine. In *Findings of the Association for Computational Linguistics: ACL 2024*, Lun-Wei Ku, Andre Martins, and Vivek Srikumar (Eds.). Association for Computational Linguistics, Bangkok, Thailand, 6233–6251. doi:10.18653/v1/2024.findings-acl.372
- [44] Guoli Xiong, Zhijiang Yang, Jiakai Yi, Ningning Wang, Lei Wang, Huimin Zhu, Chengkun Wu, Aiping Lu, Xiang Chen, Shao Liu, et al. 2022. DDInter: an online drug–drug interaction database towards improving clinical decision-making and patient safety. *Nucleic acids research* 50, D1 (2022), D1200–D1207.
- [45] Jin Y Yen. 1971. Finding the k shortest loopless paths in a network. *management Science* 17, 11 (1971), 712–716.
- [46] Yue Yu, Kexin Huang, Chao Zhang, Lucas M Glass, Jimeng Sun, and Cao Xiao. 2021. SumGNN: multi-typed drug interaction prediction via efficient knowledge graph summarization. *Bioinformatics* 37, 18 (2021), 2988–2995.
- [47] Yongqi Zhang, Quanming Yao, Ling Yue, Xian Wu, Ziheng Zhang, Zhenxi Lin, and Yefeng Zheng. 2023. Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network. arXiv:2311.09261 [q-bio.QM] <https://arxiv.org/abs/2311.09261>
- [48] Marinka Zitnik, Monica Agrawal, and Jure Leskovec. 2018. Modeling polypharmacy side effects with graph convolutional networks. *Bioinformatics* 34, 13 (2018), i457–i466.

## A LLM Prompting

We use the following prompt templates across datasets. As shown below, we provide predefined answer options for the DDInter and PharmacotherapyDB datasets. However, we do not include options for the DrugBank dataset for two reasons: (1) DrugBank contains 86 possible interaction types, making inference for approximately 30,000 examples computationally expensive. and (2) preliminary experiments showed that the model performed better without predefined options. As baselines, we either exclude knowledge graph information entirely or provide textual definitions of the drugs or diseases.

### Unified Prompt Template

#### Unified Prompt Box

##### System Prompt:

You are a pharmacodynamics expert. Answer the prompt (##Prompt) using the given knowledge graph information (if available), essential drug definitions, and your medical

expertise.

Base your answer on evidence of known interaction mechanisms, pharmacological effects, or similarities to related compounds, if applicable. Avoid generalizations unless directly supported.

Your answer must be concise and formatted as follows:  
##Answer:<Dataset Specific>

#### Dataset-Specific Instructions:

- **DDInter:** Assess drug-drug interaction severity and format as: **Answer:** <Major / Moderate / Minor>
- **PharmacotherapyDB:** Determine therapeutic indication and format as: **Answer:** <Disease modifying / Palliates / Nonindication>
- **DrugBank:** Identify mechanism or effect type and format as: **Answer:** <DrugX mechanism/effect on DrugY>

#### Sample Prompt:

Determine the interaction type or therapeutic indication when (EntityX) and (EntityY) are used together.

#### Knowledge Graph Information:

<Knowledge graph data>

## B QLoRA Fine-tuning

For the supervised LLM experiments, we fine-tuned Llama 3.1 8B Instruct using QLoRA. We conducted training experiments under two distinct scenarios across our datasets. In the first scenario, we trained the model using the retrieved paths for each training query. In the second scenario, we trained the model using text definitions of the drugs or diseases. To manage excessively long definitions, we truncated each entity definition to a maximum of 200 tokens.

In both scenarios, we trained for 10 epochs using the same settings as the QLoRA repository, with the following modifications: We adopted a learning rate of 1e-3 and set the maximum input length to the average token length of the input across the respective dataset. The training was conducted on 8 A100-80G GPUs and typically completed within 24 hours, depending on the dataset. During inference, we first retrieved reasoning paths using K-Paths. These retrieved paths were then appended to the original query and fed into the fine-tuned LLM to generate the final answers.

## C GNN Baselines

In this section we explain the GNN models used in our study

### C.1 Relational Graph Convolutional Network (RGCN)

We implement the Relational Graph Convolutional Network (RGCN) [37], which operates on the augmented graph with multiple relation types and employs message passing to propagate structured information across nodes. The model is implemented using PyTorch and PyTorch Geometric.

**C.1.1 Node Feature Initialization.** The initialization of node features follows a hybrid approach. Drug and disease nodes are initialized using RoBERTa [31] embeddings extracted from their PubMed-scraped descriptions. Other entity nodes (genes, anatomy, etc.) are initialized randomly, allowing the model to learn meaningful representations during training.

**C.1.2 Training Setup.** We follow the inductive setting for dataset splitting, as described in Section 4.1. The training follows a link prediction framework where training nodes are sampled with all their relations observed, while test nodes are introduced to evaluate generalization. We consider two training settings:

- (1) Training on the entire augmented KG *Complete KG* and testing on test nodes along with their retrieved test KG.
- (2) Training on the diverse retrieved train paths and testing on test nodes along with their retrieved test paths.

**C.1.3 Model Architecture & Training Details.** The RGCN model is trained using stochastic gradient descent with the Adam optimizer, along with a learning rate scheduler that dynamically adjusts the learning rate based on validation loss. The training loss is computed using cross-entropy loss, applied to the predicted drug-drug or drug-disease interactions. Training runs for 1,000 epochs, with early stopping based on validation loss. To maintain a balanced class representation, stratified sampling is employed, selecting a maximum of 1,000 samples per epoch and up to 10 samples per class. The model consists of three layers of relational graph convolution (GCN layers), each followed by a ReLU activation function. Node embeddings are projected into a 128-dimensional space, then processed through batch normalization, ReLU activation, and dropout with a rate of 0.5 to prevent overfitting. For interaction prediction, a separate edge classifier takes the final node embeddings of two entities and predicts their interaction type. To improve computational efficiency, the model employs basis decomposition with two bases. The learning rate is set to 1e-3, ensuring stable convergence while training.

## C.2 EmerGNN

To compare against RGCN, we evaluate EmerGNN, a graph neural network designed for emerging drug-drug interaction prediction [47]. We use the official implementation and apply it to our datasets without modifying the model architecture or training pipeline. Unlike RGCN, which relies on RoBERTa embeddings for node initialization, EmerGNN incorporates molecular features, leveraging structural and chemical properties to enhance node representation. We compare the performance of both models in terms of interaction prediction accuracy, assessing the impact of different node initialization strategies and augmented KG utilization.

## D Additional Experimental Results

This section presents additional experimental results, including retrieved paths from the augmented KG, dataset statistics, path retrieval efficiency, and model performance comparisons.

Dataset	Task	Two Nodes	Single Nodes	No Node
DrugBank (Ind.)	Open-ended	27,983	3,987	14
DrugBank (Trans.)	Open-ended	38,411	8	0
DDInter	Categorical	13,841	5,494	104
Drug Repurposing	Categorical	252	0	0

**Table 6: Summary of datasets and tasks.**

Model	Setting	Accuracy	F1	Kappa
<b>Graph-Based Models (GNNs)</b>				
EmerGNN	Complete KG	<b>97.40</b>	94.00	96.60
EmerGNN	K-Paths	97.01	<b>94.25</b>	<b>97.01</b>
RGCN	Complete KG	90.01	87.62	89.85
RGCN	K-Paths	90.86	88.43	90.11
SumGNN	Reported	86.85	92.66	92.66
KnowDDI	Reported	91.53	93.17	91.89
<b>LLM-Based Models</b>				
QLoRA-Llama	Definitions	93.45	91.71	92.28
QLoRA-Llama	K-Paths	93.58	88.98	92.41

**Table 7: Performance of various models on the Transductive DrugBank setting. Bold indicates the best performance, and underlined denotes the second-best. LLMs leverage both knowledge types effectively with supervision, and K-Paths enhance GNN efficiency without significant performance loss.**

## D.1 Dataset Overview

Table 6 summarizes the datasets used in our experiments, categorized by prediction task and the connectivity between interaction query nodes (entities) in the augmented KG.

- DrugBank involves inductive and transductive tasks, predicting drug-drug interactions among 86 labels. The transductive setting has more drug pairs connected in the augmented KG (38,411) than the inductive setting (27,983).
- DDInter predicts drug-drug interaction severity levels (Major, Moderate, or Minor). It contains 13,367 connecting drug pairs, and 5,909 interaction queries contain information about a single entity.
- Drug repurposing focuses on whether a drug is disease-modifying, palliates, or has no indication of a disease.

## D.2 Transductive Results

Table 7 compares the performance of Graph Neural Networks (GNNs) and LLM-based models on the Drugbank transductive dataset. Among GNNs, EmerGNN performs best, achieving 97.40% accuracy with the complete KG, while using our KG slightly lowers accuracy (97.01%) but improves the F1-score. RGCN performs worse than EmerGNN but benefits from our KG, increasing accuracy from 90.01% to 90.86%. For LLM-based models, QLoRA-Llama achieves 93.58% accuracy when using K-Paths, while using text-based descriptions instead of structured knowledge results in similar accuracy (93.45%) but a slightly higher F1-score. Overall, EmerGNN performs best and K-Paths improves efficiency without significant performance loss.

Dataset	Before Retrieval (Augmented KG)			After Retrieval (K-Paths)		
	#Nodes	#Relations	#Triplets	#Nodes	#Relations	#Triplets
DrugBank	35,146	102	1,722,677	6,378	94	175,698
DDInter	35,169	26	1,710,079	5,647	18	102,854
PharmacotherapyDB	33,952	26	1,690,945	2,847	23	13,942

**Table 8: Statistics: Comparison of the Augmented KG with extracted subgraph at test time.**

Relation ID	Description	Retained for DrugBank	Retained for DDInter	Retained for PharmacotherapyDB
0	Anatomy-downregulates-Gene (AdG)	×	×	✓
1	Anatomy-expresses-Gene (AeG)	×	×	✓
2	Anatomy-upregulates-Gene (AuG)	×	×	✓
3	Compound-binds-Gene (CbG)	✓	✓	✓
4	Compound-causes-Side Effect (CcSE)	✓	✓	✓
5	Compound-downregulates-Gene (CdG)	✓	✓	✓
6	Compound-palliates-Disease (CpD)	✓	✓	✓
7	Compound-resembles-Compound (CrC)	✓	✓	✓
8	Compound-treats-Disease (CtD)	✓	✓	✓
9	Compound-upregulates-Gene (CuG)	✓	✓	✓
10	Disease-associates-Gene (DaG)	✓	✓	✓
11	Disease-downregulates-Gene (DdG)	✓	✓	✓
12	Disease-localizes-Anatomy (DLA)	×	×	✓
13	Disease-presents-Symptom (DpS)	×	×	✓
14	Disease-resembles-Disease (DrD)	✓	✓	✓
15	Disease-upregulates-Gene (DuG)	✓	✓	✓
16	Gene-covaries-Gene (GcG)	✓	✓	✓
17	Gene-interacts-Gene (GiG)	✓	✓	✓
18	Gene-participates-Biological Process (GpBP)	×	×	×
19	Gene-participates-Cellular Component (GpCC)	×	×	×
20	Gene-participates-Molecular Function (GpMF)	×	×	×
21	Gene-participates-Pathway (GpPW)	×	×	×
22	Gene→regulates→Gene (GrG)	✓	✓	✓
23	Pharmacologic Class-includes-Compound (PCiC)	✓	✓	✓

**Table 9: Hetionet relations retained by K-Paths for each dataset. ✓ indicates presence, × indicates absence.**

### D.3 Comparison of the augmented KG and the Subgraph Extracted at Test Time

Table 8 compares the augmented KG’s overall structure to the subgraph extracted at test time. We report the number of nodes, relations, and triplets before and after query-specific retrieval. Filtering for relevant subgraphs significantly reduces graph size: DrugBank shrinks from 1.7M to 175K triplets, DDInter from 1.71M to 102K, and PharmacotherapyDB from 1.69M to 13K. This demonstrates the efficiency of query-specific retrieval in extracting only the most relevant paths for inference.

- Hetionet originally contained 23 distinct relation types, covering diverse biological interactions.
- After dataset-specific path extraction, only 15 relation types were retained by K-Paths and used for training, ensuring that only the most relevant interactions contributed to the model.

Interestingly, while PharmacotherapyDB is the smallest dataset, it retains more relations than DrugBank and DDInter. This is because PharmacotherapyDB encompasses both drug and disease entities, covering a broader set of biomedical interactions that span multiple domains.

### D.4 Hetionet Relations Retained Across Datasets

Table 9 presents the Hetionet relations retained in the training and test subgraphs after K-Paths was applied to each dataset. These relations encapsulate biological interactions, such as gene participation in molecular functions (GpMF) or compounds treating diseases (CtD).

Since Hetionet serves as a structured biomedical KG, these relations may not be inherent to the datasets (DrugBank, DDInter, PharmacotherapyDB) themselves but instead provide additional contextual knowledge that enhances reasoning within the models. The path retrieval process selectively retains the most informative relations while discarding those less relevant to each dataset.

For example, in the DDInter dataset: